129 related articles for article (PubMed ID: 10733123)
21. The immunohistochemical expression of cathepsin D in colorectal cancer.
Valentini AM; Pirrelli M; Armentano R; Caruso ML
Anticancer Res; 1996; 16(1):77-80. PubMed ID: 8615673
[TBL] [Abstract][Full Text] [Related]
22. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
Kusaba T; Nakayama T; Yamazumi K; Yakata Y; Yoshizaki A; Nagayasu T; Sekine I
J Clin Pathol; 2005 Aug; 58(8):833-8. PubMed ID: 16049285
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of lymphatic invasion of colorectal cancer: a single-center analysis of 1,616 patients over 24 years.
Akagi Y; Adachi Y; Ohchi T; Kinugasa T; Shirouzu K
Anticancer Res; 2013 Jul; 33(7):2965-70. PubMed ID: 23780987
[TBL] [Abstract][Full Text] [Related]
24. [Cathepsin D expression in primary breast cancer. Comparison of immunohistochemical and biochemical results].
Göhring UJ; Ingenhorst A; Crombach G; Scharl A
Pathologe; 1993 Dec; 14(6):313-7. PubMed ID: 8121884
[TBL] [Abstract][Full Text] [Related]
25. Distribution of carcinoembryonic antigen and biologic behavior in colorectal carcinoma.
Kim JC; Han MS; Lee HK; Kim WS; Park SK; Park KC; Bodmer WF; Rowan AJ; Kim OJ
Dis Colon Rectum; 1999 May; 42(5):640-8. PubMed ID: 10344687
[TBL] [Abstract][Full Text] [Related]
26. Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival.
Huh JW; Kim HC; Kim SH; Park YA; Cho YB; Yun SH; Lee WY; Chun HK
J Surg Oncol; 2014 Jun; 109(8):848-52. PubMed ID: 24623275
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices.
Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ
Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report.
Tumminello FM; Gebbia N; Pizzolanti G; Russo A; Bazan V; Leto G
Oncology; 1995; 52(3):237-42. PubMed ID: 7715907
[TBL] [Abstract][Full Text] [Related]
29. Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths.
Ogawa T; Yoshida T; Tsuruta T; Tokuyama W; Adachi S; Kikuchi M; Mikami T; Saigenji K; Okayasu I
Scand J Gastroenterol; 2009; 44(5):605-14. PubMed ID: 19221929
[TBL] [Abstract][Full Text] [Related]
30. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma.
Okuyama T; Oya M; Ishikawa H
Dis Colon Rectum; 2002 May; 45(5):628-34. PubMed ID: 12004212
[TBL] [Abstract][Full Text] [Related]
31. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma.
Nazeer T; Malfetano JH; Rosano TG; Ross JS
Am J Clin Pathol; 1992 Jun; 97(6):764-9. PubMed ID: 1595596
[TBL] [Abstract][Full Text] [Related]
32. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40.
Walgenbach-Bruenagel G; Tolba RH; Varnai AD; Bollmann M; Hirner A; Walgenbach KJ
Eur Surg Res; 2006; 38(5):438-44. PubMed ID: 16912482
[TBL] [Abstract][Full Text] [Related]
33. Pre-treatment staging of colorectal cancer. American College of Radiology. ACR Appropriateness Criteria.
Megibow AJ; Ralls PW; Balfe DM; Bree RL; DiSantis DJ; Glick SN; Levine MS; Saini S; Shuman WP; Greene FL; Laine LA; Lillemoe K; Mezwa D
Radiology; 2000 Jun; 215 Suppl():135-42. PubMed ID: 11037418
[No Abstract] [Full Text] [Related]
34. Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast.
Fernandez-Aguilar S; Noël JC
APMIS; 2008 Jan; 116(1):33-40. PubMed ID: 18254778
[TBL] [Abstract][Full Text] [Related]
35. Tumour budding intensity in relation to cathepsin D expression and some clinicopathological features of colorectal cancer.
Famulski W; Guzińska-Ustymowicz K; Sulkowska M; Chabowski A; Zalewski B; Piotrowski Z; Stasiak-Barmuta A; Sulkowski S
Folia Histochem Cytobiol; 2001; 39 Suppl 2():171-2. PubMed ID: 11820592
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical evaluation of cathepsin D expression in colorectal cancer.
Chabowski A; Sulkowska M; Sulkowski M; Famulski W; Skrzydlewska E; Kisielewski W
Folia Histochem Cytobiol; 2001; 39(2):153-4. PubMed ID: 11374801
[TBL] [Abstract][Full Text] [Related]
37. The Immunohistochemical expression of endothelial cell differentiation gene-2 receptor in human colorectal adenomas.
Komuro Y; Watanabe T; Kitayama J; Yamaguchi H; Tsuno N; Nagawa H
Hepatogastroenterology; 2003; 50(54):1770-3. PubMed ID: 14696401
[TBL] [Abstract][Full Text] [Related]
38. Significance of immunohistochemical expression of manganese superoxide dismutase as a marker of malignant potential in colorectal carcinoma.
Nozoe T; Honda M; Inutsuka S; Yasuda M; Korenaga D
Oncol Rep; 2003; 10(1):39-43. PubMed ID: 12469142
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma.
Sis B; Sağol O; Küpelioğlu A; Sokmen S; Terzi C; Fuzun M; Ozer E; Bishop P
Pathol Res Pract; 2004; 200(5):379-87. PubMed ID: 15239346
[TBL] [Abstract][Full Text] [Related]
40. Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.
Li JQ; Miki H; Ohmori M; Wu F; Funamoto Y
Hum Pathol; 2001 Sep; 32(9):945-53. PubMed ID: 11567224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
